AlloVir (Nasdaq: ALVR) on Friday saw its shares plunge more than 67% to $0.77, after it announced discontinuation of its three Phase III studies for its lead asset posoleucel, an allogeneic T cell immunotherapy company.
The decision was based on pre-planned futility analyses by the Data Safety Monitoring Boards (DSMB) indicating studies were unlikely to meet their primary endpoints (despite no safety concerns raised). AlloVir pointed out that none of the boards had raised any safety concerns.
Posoleucel is an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze